Andrew H. Ko, MD graduated magna cum laude from Brown University and received his medical degree from Johns Hopkins School of Medicine. After an internship and residency at Beth Israel Hospital in Boston, he completed a fellowship in medical oncology at Stanford University before joining the UCSF faculty in 2001.
Dr. Ko, a former recipient of a Career Development Award from the American Society of Clinical Oncology (ASCO), specializes in the treatment of malignancies of the gastrointestinal tract. His particular clinical and research focus is in pancreatic and gastroesophageal cancer, where he has led and been involved in the development and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to immunotherapies. He has been interested in identifying individual patient/tumor characteristics that influence prognosis and response to specific therapies, including both tissue- and blood-based biomarkers. He has collaborated with members of UCSF’s Department of Biostatistics and Epidemiology on an NIH-funded clinic-based case-control study together to identify protective and risk factors for pancreatic cancer that may inform screening strategies as well as potentially modifiable behavioral or pharmacologic interventions to reduce incidence and mortality associated with this disease.
At UCSF, Dr. Ko heads the GI site committee where he works closely with colleagues in the development and oversight of trials focused on pancreatic, colorectal, hepatobiliary, esophagogastric, and neuroendocrine malignancies. He also chairs the Cancer Center’s scientific Protocol Review Committee. Nationally, he has served on the scientific program and grants review committees for ASCO; is currently the representative for the Alliance cooperative group on the National Cancer Institute’s Pancreatic Cancer Task Force; sits on the National Comprehensive Cancer Network (NCCN) Pancreatic Cancer guidelines committee; and serves as Associate Editor for the Journal of Clinical Oncology.